Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 2/20 | 0.42 |
| ▸ | CNR1 | P21554 | 11/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | TNKS | O95271 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 6/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | PI4KA | P42356 | 1/20 | 0.38 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.38 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1688878 | 0.90 | CNR1 (0.42) | GRM1CNR1KCNH2TNKSCNR2 | |
| SCHEMBL1753295 | 0.88 | HSD11B1 (0.44) | CNR1HSD11B1KCNH2CNR2KDM4E | |
| SCHEMBL1689114 | 0.87 | CNR1 (0.45) | GRM1CNR1KCNH2TNKSCNR2 | |
| SCHEMBL1753306 | 0.87 | CNR1 (0.45) | CNR1KCNH2TNKSCNR2KMT2A | |
| SCHEMBL1753456 | 0.85 | HSD11B1 (0.47) | CNR1HSD11B1KCNH2TNKSCNR2 | |
| SCHEMBL1753407 | 0.85 | CNR1 (0.44) | CNR1KCNH2TNKSCNR2KMT2A | |
| SCHEMBL1753248 | 0.85 | CNR1 (0.44) | CNR1KCNH2TNKSCNR2KMT2A | |
| SCHEMBL1753260 | 0.85 | CNR1 (0.41) | CNR1KCNH2TNKSCNR2 | |
| SCHEMBL1753612 | 0.84 | HSD11B1 (0.42) | GRM1CNR1HSD11B1KCNH2TNKS | |
| SCHEMBL1688954 | 0.84 | CNR1 (0.39) | CNR1KCNH2TNKSCNR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120225869-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2012-09-06 | — | — | US | claimed |
| US-20090247517-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2009-10-01 | — | — | US | claimed |
| US-20120225869-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2012-09-06 | — | — | US | disclosed |
| US-20120225869-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2012-09-06 | — | — | US | disclosed |
| US-20120225869-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2012-09-06 | — | — | US | disclosed |
| US-8158634-B2 | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity | IRM LLC (BM) | 2012-04-17 | — | — | US | disclosed |
| US-8158634-B2 | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity | IRM LLC (BM) | 2012-04-17 | — | — | US | disclosed |
| US-8158634-B2 | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity | IRM LLC (BM) | 2012-04-17 | — | — | US | disclosed |
| US-20090247517-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2009-10-01 | — | — | US | disclosed |
| US-20090247517-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2009-10-01 | — | — | US | disclosed |
| US-20090247517-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225869-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | CNR1, CNR2, FAAH | GRM1 69/4885CNR1 1/4885HSD11B1 1978/4885 |
| US-20090247517-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | CNR1, CNR2, FAAH | GRM1 69/4885CNR1 1/4885HSD11B1 1978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.